Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Patterson

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Experimental Hematology|September 1, 2007
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu miceDaniel Ditzel Santos, Allen W Ho, Olivier Tournilhac, et al.
Blood|August 21, 2008
Thalidomide and rituximab in Waldenstrom macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Blood Cancer Journal|February 2, 2020
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomasManit Munshi, Xia Liu, Jiaji G Chen, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Experimental Hematology|September 1, 2007
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu miceDaniel Ditzel Santos, Allen W Ho, Olivier Tournilhac, et al.
Blood|August 21, 2008
Thalidomide and rituximab in Waldenstrom macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Blood Cancer Journal|February 2, 2020
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomasManit Munshi, Xia Liu, Jiaji G Chen, et al.
Pageof 11